Interestingly, they already combined R‐2‐HG inhibition with radiotherapy, TMZ, and anti‐PDL1 ICB, and observed complete tumor regression in 60% of IDH‐mutant glioma‐bearing mice. This evidence concerns the gene IDH2 and central nervous system cancer.